San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the tumor microenvironment and healthy tissue.

BioAtla (BCAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. SAN DIEGO, Dec ...

SAN DIEGO, CA – BioAtla, Inc., a biotechnology firm specializing in biological products, received notice from The Nasdaq Stock Market on Tuesday that it is at risk of being delisted. Currently ...